Surface Oncology

NASDAQ:SURF
Developing next-generation antibody therapies focused on the tumor microenvironment.

F-Prime Team

Sector

Life Sciences

Category

Therapeutics

Location

Cambridge, MA

Initial Investment

2014
Developing next-generation antibody therapies focused on the tumor microenvironment.

Surface Oncology (NASDAQ:SURF) is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment with lead programs targeting CD73, CD39, IL-27 and CD47. Surface Oncology was acquired by Coherus BioSciences.